Introduction
Sarcopenia, the progressive loss of skeletal muscle mass, is increasingly recognized as a critical prognostic factor in oncology. While the skeletal muscle area at the third lumbar vertebra (L3) is the current "gold standard" for assessment, routine chest CT scans for non-small cell lung cancer (NSCLC) patients often exclude this region. This study evaluates the Pectoralis Muscle Index (PMI)—measured at the fourth thoracic vertebra (T4)—as a practical, radiation-free alternative for predicting distant metastasis-free survival (DMFS) and recurrence-free survival (RFS).
Methodology
This retrospective study analyzed a cohort of 2,110 patients with stage I–IIIA NSCLC who underwent curative surgery at the Yunnan Cancer Center between 2013 and 2018.
Researchers utilized specialized software to manually segment the pectoralis major and minor muscles on unenhanced CT images at the T4 level. The PMI was calculated by normalizing the total muscle area by the square of the patient's height (cm²/m²). Sex-specific thresholds for "low PMI" were determined using X-tile software.
Key Results
The analysis demonstrated that low preoperative PMI is a robust independent predictor of poor clinical outcomes:
- Distant Metastasis-Free Survival (DMFS): Patients with low PMI faced a significantly higher risk of distant spread (Hazard Ratio [HR] = 1.40).
- Recurrence-Free Survival (RFS): Low PMI was independently associated with cancer recurrence (HR = 1.39).
- Organ-Specific Metastasis: Low muscle mass specifically predicted increased metastasis to the lungs (HR = 1.53) and bones (HR = 1.42).
Notably, a Gradient Boosting Model (GBM) ranked PMI as the third most influential predictor for recurrence, surpassing traditional clinical markers such as age, BMI, and smoking history.
Discussion and Clinical Implications
The study confirmed a significant correlation (Pearson’s Rho = 0.63) between T4 and L3 muscle measurements, validating the pectoralis muscles as a viable proxy for systemic muscle status. Beyond physical strength, skeletal muscle serves as an endocrine organ, releasing myokines like IL-7 and IL-15 that modulate the immune system. Consequently, low PMI may reflect a compromised immune environment conducive to metastatic progression.
By utilizing data already present in standard-of-care imaging, clinicians can refine risk stratification without additional costs or radiation exposure. This "hidden" body composition data provides a powerful tool for identifying high-risk patients who may require more intensive postoperative monitoring.
Limitations
While promising, the study's findings are based on a single-center Asian population, and the specific PMI cut-offs may require adjustment for other ethnic groups. Future research should focus on longitudinal muscle changes during treatment to better understand the dynamic relationship between body composition and survival.
Summary updated